287 related articles for article (PubMed ID: 9224752)
1. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization.
Ross JS; Sheehan C; Hayner-Buchan AM; Ambros RA; Kallakury BV; Kaufman R; Fisher HA; Muraca PJ
Hum Pathol; 1997 Jul; 28(7):827-33. PubMed ID: 9224752
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma.
Ross JS; Sheehan CE; Hayner-Buchan AM; Ambros RA; Kallakury BV; Kaufman RP; Fisher HA; Rifkin MD; Muraca PJ
Cancer; 1997 Jun; 79(11):2162-70. PubMed ID: 9179063
[TBL] [Abstract][Full Text] [Related]
3. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
[TBL] [Abstract][Full Text] [Related]
4. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.
Riben MW; Malfetano JH; Nazeer T; Muraca PJ; Ambros RA; Ross JS
Mod Pathol; 1997 Aug; 10(8):823-31. PubMed ID: 9267826
[TBL] [Abstract][Full Text] [Related]
5. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
[TBL] [Abstract][Full Text] [Related]
6. Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas.
Kallakury BV; Sheehan CE; Ambros RA; Fisher HA; Kaufman RP; Muraca PJ; Ross JS
J Clin Oncol; 1998 Apr; 16(4):1302-9. PubMed ID: 9552030
[TBL] [Abstract][Full Text] [Related]
7. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
Pauletti G; Dandekar S; Rong H; Ramos L; Peng H; Seshadri R; Slamon DJ
J Clin Oncol; 2000 Nov; 18(21):3651-64. PubMed ID: 11054438
[TBL] [Abstract][Full Text] [Related]
8. Cell proliferation rate by MIB-1 immunohistochemistry predicts postradiation recurrence in prostatic adenocarcinomas.
Scalzo DA; Kallakury BV; Gaddipati RV; Sheehan CE; Keys HM; Savage D; Ross JS
Am J Clin Pathol; 1998 Feb; 109(2):163-8. PubMed ID: 9583887
[TBL] [Abstract][Full Text] [Related]
9. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray.
Skacel M; Ormsby AH; Pettay JD; Tsiftsakis EK; Liou LS; Klein EA; Levin HS; Zippe CD; Tubbs RR
Hum Pathol; 2001 Dec; 32(12):1392-7. PubMed ID: 11774175
[TBL] [Abstract][Full Text] [Related]
10. Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome.
Peiró G; Mayr D; Hillemanns P; Löhrs U; Diebold J
Mod Pathol; 2004 Mar; 17(3):227-87. PubMed ID: 14752523
[TBL] [Abstract][Full Text] [Related]
11. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.
Hammock L; Lewis M; Phillips C; Cohen C
Hum Pathol; 2003 Oct; 34(10):1043-7. PubMed ID: 14608539
[TBL] [Abstract][Full Text] [Related]
12. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression.
Tsuda H; Akiyama F; Terasaki H; Hasegawa T; Kurosumi M; Shimadzu M; Yamamori S; Sakamoto G
Cancer; 2001 Dec; 92(12):2965-74. PubMed ID: 11753973
[TBL] [Abstract][Full Text] [Related]
13. Her-2/neu Oncogene Amplification by Fluorescence In Situ Hybridization and Protein Overexpression on Immunohistochemistry in Breast Cancer.
Lateef F; Jamal S; Nasir S
J Coll Physicians Surg Pak; 2018 Aug; 28(8):581-585. PubMed ID: 30060783
[TBL] [Abstract][Full Text] [Related]
14. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays.
Wang S; Saboorian MH; Frenkel E; Hynan L; Gokaslan ST; Ashfaq R
J Clin Pathol; 2000 May; 53(5):374-81. PubMed ID: 10889820
[TBL] [Abstract][Full Text] [Related]
15. HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer.
Bozzetti C; Nizzoli R; Guazzi A; Flora M; Bassano C; Crafa P; Naldi N; Cascinu S
Ann Oncol; 2002 Sep; 13(9):1398-403. PubMed ID: 12196365
[TBL] [Abstract][Full Text] [Related]
16. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization.
Lebeau A; Deimling D; Kaltz C; Sendelhofert A; Iff A; Luthardt B; Untch M; Löhrs U
J Clin Oncol; 2001 Jan; 19(2):354-63. PubMed ID: 11208826
[TBL] [Abstract][Full Text] [Related]
17. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
[TBL] [Abstract][Full Text] [Related]
18. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
[TBL] [Abstract][Full Text] [Related]
19. Her-2/neu gene amplification and protein expression in primary male breast cancer.
Rudlowski C; Friedrichs N; Faridi A; Füzesi L; Moll R; Bastert G; Rath W; Büttner R
Breast Cancer Res Treat; 2004 Apr; 84(3):215-23. PubMed ID: 15026619
[TBL] [Abstract][Full Text] [Related]
20. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.
Liu W; Zhong S; Chen J; Yu Y
J Clin Gastroenterol; 2012 Apr; 46(4):e31-7. PubMed ID: 22064554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]